Home » Stocks » DSGN

Design Therapeutics, Inc. (DSGN)

Stock Price: $26.60 USD -2.76 (-9.40%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
After-hours: $26.62 +0.02 (0.08%) Apr 9, 5:50 PM
Market Cap 1.43B
Revenue (ttm) 226,000
Net Income (ttm) -8.28M
Shares Out 53.82M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $26.60
Previous Close $29.36
Change ($) -2.76
Change (%) -9.40%
Day's Open 29.35
Day's Range 26.40 - 29.93
Day's Volume 94,907
52-Week Range 25.27 - 50.50


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...

1 week ago - GlobeNewsWire

CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...

2 weeks ago - GlobeNewsWire

Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Design Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About DSGN

Design Therapeutics is a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases, of which there are more than 40 debilitating degenerative diseases. Individuals with nucleotide repeat expansion diseases are born with abnormally expanded stretches of specific nucleotide sequences, often with hundreds to thousands of excess repeats present... [Read more...]

IPO Date
Mar 26, 2021
Jou00e3o Siffert, M.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, DSGN's revenue was $226,000, a decrease of -72.90% compared to the previous year's $834,000. Losses were -$8.28 million, 304.5% more than in 2019.

Financial Statements